Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era
Open Access
- 1 February 2018
- journal article
- research article
- Published by Elsevier in International Journal of Drug Policy
- Vol. 52, 115-122
Abstract
No abstract availableKeywords
Funding Information
- Health Protection Scotland
This publication has 34 references indexed in Scilit:
- Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic reviewThe Lancet Global Health, 2017
- Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United StatesAnnals of Internal Medicine, 2015
- EASL Recommendations on Treatment of Hepatitis C 2015Journal of Hepatology, 2015
- Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: the ETHOS studyJournal of Viral Hepatitis, 2015
- Hepatitis C Virus Therapeutic Development: In Pursuit of "Perfectovir"Clinical Infectious Diseases, 2015
- Prevention, treatment and care of hepatitis C virus infection among people who inject drugsInternational Journal of Drug Policy, 2015
- Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono‐infected and HCV/HIV co‐infected adultsJournal of Viral Hepatitis, 2013
- Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriersJournal of Viral Hepatitis, 2012
- Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in ScotlandInternational Journal of Drug Policy, 2012
- Self-report among injecting drug users: A reviewDrug and Alcohol Dependence, 1998